A Study of Ivonescimab in First-Line ES-SCLC

NCT07245446 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: Ivonescimab
DRUG: Cadonilimab
DRUG: AK117
DRUG: Etoposide
DRUG: Carboplatin (AUC 5)

Sponsor

Akeso